Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Neurocrine's revenue rose 41.2% year over year to $1.1B in 2026Q3 after 39.5% growth in Q2, suggesting durable commercial momentum, while operating margin expanded from 22.6% in 2024Q4 to 29.5% in 2026Q3 and free cash flow reached $383.6M in the latest quarter.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue and operating margin have improved strongly, with quarterly revenue reaching $1.1B and operating margin rising to 29.5% in 2026Q3, although the trend has been volatile, with margin dipping to 4.1% in 2025Q1.
Neurocrine Biosciences presented a retrospective case series of CRENESSITY for patients with classic congenital adrenal hyperplasia, showcasing potential therapeutic benefits.
MarketBeat and other platforms provide stock analysis, price targets, and earnings estimates for NBIX, indicating strong institutional interest.
The presentation of CRENESSITY at ENDO 2026 highlights Neurocrine's ongoing pipeline development and potential for future growth.
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 2, 2026 | $3.29+72.3% vs $1.91 | $1.1B+7.6% vs $1.0B |
Q3 2026 Jul 30, 2026 | $2.85+54.1% vs $1.85 | $959M+7.7% vs $890M |
Q2 2026 May 5, 2026 | $1.91+56.6% vs $1.22 | $815M+6.0% vs $768M |
Q1 2026 Feb 11, 2026 | $1.88+4.4% vs $1.80 | $806M+1.9% vs $790M |
Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Eurizon Capital SGR S.p.A. trimmed its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 20.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 40,121 shares of the company's stock after selling 10,154 shares during the quarter. Eurizon Capital SGR
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Guardian Pharmacy Services (GRDN). But which of these two stocks presents investors with the better value opportunity right now?
Benchmark NBIX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Neurocrine Biosciences, Inc. (NBIX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $165.92 | $16.68B | 24.85 | 21.45% | 18.98% | 19.74% | — | |
| $18.30 | $1.35B | 6.82 | 18.52% | 43.79% | 15.84% | — | |
| $18.32 | $3.14B | 8.87 | 11.87% | 30.13% | 28.03% | — | |
| $60.36 | $5.01B | -47.55 | 114.51% | -9.17% | — | — | |
| $16.70 | $1.64B | -3.25 | 20.13% | -71.78% | — | — | |
| $15.76 | $2.18B | -1.24 | -2.75% | -43.27% | -68.13% | 7.3% |
Neurocrine Biosciences, Inc. (NBIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Neurocrine Biosciences, Inc. (NBIX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 2, 2026·SEC
Jul 30, 2026·SEC
May 28, 2026·SEC
Get notified when NBIX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Neurocrine Biosciences, Inc. (NBIX) stock FAQ — growth, dividends, profitability & financials explained
Neurocrine Biosciences, Inc. (NBIX) reported $3.70B in revenue over the trailing twelve months. Revenue was $2.86B in fiscal year 2025. That is 14798% more than the $19.2M of fiscal year 1996.
Neurocrine Biosciences, Inc. (NBIX) grew revenue by 38.0% over the trailing twelve months, compared with the twelve months before.
Yes. Neurocrine Biosciences, Inc. (NBIX) earned $702.5M in net income over the trailing twelve months (a 19.0% net margin).
Neurocrine Biosciences, Inc. (NBIX) had a return on equity (ROE) of 19.7% over the trailing twelve months. That is above the market's typical 10-15%.
Neurocrine Biosciences, Inc. (NBIX) generated $1.04B in free cash flow over the trailing twelve months.